{"id":267,"date":"2025-08-30T16:45:47","date_gmt":"2025-08-30T09:45:47","guid":{"rendered":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/"},"modified":"2025-08-30T16:45:47","modified_gmt":"2025-08-30T09:45:47","slug":"fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina","status":"publish","type":"post","link":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/","title":{"rendered":"Fosun pharma untuk secara eksklusif mengembangkan bioscience anti-inflamasi di Cina"},"content":{"rendered":"<div>\n<div class=\"\">\n<div style=\"width:30%;float:left;max-width:525px;margin:0 1.5rem 1.5rem 0;clear:both;cursor:\" class=\" figure\">\n<div id=\"image-caption\" class=\"text-gray-500 italic\">\n<div class=\"blockText_blockContent__TbCXh\">\n<p class=\"pb-2\">Shanghai.China-Jan. 8th 2022: Logo Fosun Pharma Company di gedung kantor di malam hari. Perusahaan farmasi Cina yang sebagian besar dimiliki oleh Fosun International | Kredit Gambar: \u00a9 Robert &#8211; Stock.adobe.com<\/p>\n<\/div>\n<\/div>\n<div class=\"hidden top-(-100%) block w-(1px) transition-opacity duration-500 ease-in-out opacity-0 overflow-hidden\"><img decoding=\"async\" class=\"m-auto absolute inset-0 max-w-(0%) max-h-(0%) border-(3px) border-solid border-white shadow-(0px_0px_8px_rgba(0,0,0,0.3)) box-border transition ease-in-out duration-500\" src=\"https:\/\/cdn.sanity.io\/images\/0vv8moc6\/pharmtech\/c5d7149fbf2289aa45ced0d8d78cfbeaef098d2d-6240x4160.jpg?fit=crop&amp;auto=format\"\/><\/div>\n<\/div>\n<\/div>\n<p class=\"pb-2\">Shanghai-based Fosun Pharma has reached an agreement with Accro Bioscience to exclusively develop, manufacture and commercialize Accro&#39;s highly selective tyrosine kinase 2 (TYK2)\/Janus kinase 1 (JAK1) inhibitor candidate, AC-201, in Greater China, which includes the Chinese mainland and the special administrative regions of Hong Kong and Macau (1).<\/p>\n<p class=\"pb-2\">AC-201 telah dikembangkan dengan tujuan mengobati berbagai penyakit radang yang dimediasi kekebalan. Fosun Pharma mengatakan kandidat molekul kecil sedang dikembangkan dalam novel, formulasi oral, dan merupakan inhibitor kuat yang berikatan dengan domain pseudo kinase, JH2, dari Tyk2\/jak1 (1). Ada efek minimal pada jalur pensinyalan JAK2\/JAK2, menurut Fosun Pharma.<\/p>\n<p class=\"pb-2\">Fosun Pharma mengatakan bahwa AC-201 telah menyelesaikan uji klinis fase II pada pasien dengan psoriasis plak sedang hingga berat di mana semua kelompok dosis memenuhi titik akhir sekunder primer dan kunci setelah 12 minggu pengobatan (1).<\/p>\n<h2 class=\"text-2xl pb-4 pt-2\"><strong>Adakah perawatan baru lainnya untuk penyakit radang?<\/strong><\/h2>\n<p class=\"pb-2\">Pengumuman Perjanjian ini karena Agustus 2025 datang ke dekat memperkuat beberapa terapi lain untuk indikasi inflamasi yang datang ke pasar.<\/p>\n<p class=\"pb-2\">Pada 6 Agustus 2025, Celltrion mengumumkan bahwa FDA menyetujui penerapannya untuk indikasi yang diperluas dari tocilizumab-anoh (nama merek AVTOZMA), terapi intravena, untuk memasukkan pengobatan sindrom pelepasan sitokin pada orang dewasa dan pasien anak berusia 2 tahun dan lebih tua (2). Tocilizumab-anoh adalah biosimilar untuk Actemra (Tocilizumab) dan awalnya menerima persetujuan FDA pada Januari 2025 untuk mengobati beberapa indikasi inflamasi, termasuk rheumatoid arthritis, artteritis sel raksasa, arthritis corpatik, dan arthritis corpatik, dan arthritis corpatik, dan sendi sistemik.<\/p>\n<p class=\"pb-2\">Sanofi melaporkan pada 14 Agustus 2025 bahwa Badan Obat-obatan Eropa telah memberikan penunjukan yatim untuk Rilzabrutinib, inhibitor tirosin kinase bruton oral yang diselidiki, untuk pengobatan penyakit terkait IgG4 (yaitu, yang mempengaruhi imunoglobulin G4) (4). Menurut Sanofi, rilzabrutinib sedang diselidiki di beberapa penyakit yang dimediasi kekebalan dan radang yang jarang terjadi. Ini juga memiliki penunjukan yatim untuk mengobati trombositopenia kekebalan di Amerika Serikat, Uni Eropa, dan Jepang, serta untuk anemia hemolitik autoimun hangat, penyakit sel sabit, dan IgG4-RD di AS.<\/p>\n<h2 class=\"text-2xl pb-4 pt-2\"><strong>Bagaimana para pemimpin Fosun dan Accro menanggapi perjanjian tersebut?<\/strong><\/h2>\n<p class=\"pb-2\">\u201cKami senang masuk ke dalam kolaborasi ini dengan ACCRO. AC-201, sebagai inhibitor TYK2\/JAK1 yang sangat selektif, menunjukkan potensi klinis yang signifikan dalam pengobatan penyakit autoimun.\u201d Xingli Wang, MD, PhD, co-president Fosun Pharma dan CEO dari Global R&#038;D Center, mengatakan dalam siaran pers (1). \u201cFosun Pharma tetap berkomitmen untuk memperkenalkan dan mengembangkan terapi inovatif dengan signifikansi terobosan untuk memenuhi kebutuhan medis yang tidak terpenuhi. Kemitraan ini akan semakin memperkaya saluran pipa kami di bidang imunologi dan peradangan &#8230; kami berharap dapat bekerja sama dengan tim ACCRO untuk mendorong keberhasilan produk ini dan menyediakan pilihan perawatan berkualitas tinggi untuk pasien di China dan sekitar dunia.<\/p>\n<p class=\"pb-2\">&#8220;Pengalaman pengembangan klinis Fosun yang luas dan kemampuan komersialisasi akan mempercepat pengembangan AC-201 dan meningkatkan aksesibilitas obat, membawa opsi pengobatan yang luar biasa kepada pasien dengan penyakit autoimun di wilayah tersebut sesegera mungkin,&#8221; kata Xiaohu Zhang, PhD, salah satu pendiri dan CEO akro biosisi, mengatakan dalam rilis (1).<\/p>\n<p class=\"pb-2\">Fosun Pharma juga berkolaborasi dengan Biontech sebagai salah satu mitra perusahaan dalam mengembangkan terapi RNA RNA generasi berikutnya (5).<\/p>\n<p class=\"pb-2\">Berdasarkan perjanjian untuk AC-201, ACCRO Bioscience berhak atas total pembayaran RMB 80 juta (US $ 11,2 juta), yang mencakup pembayaran di muka sebesar RMB 60 juta (US $ 8,4 juta) dan pembayaran tonggak sebesar RMB 20 juta (US $ 2,8 juta) setelah penyelesaian transfer manufaktur, serta paying RMB.<\/p>\n<h2 class=\"text-2xl pb-4 pt-2\"><strong>Referensi<\/strong><\/h2>\n<p class=\"pb-2\">1. Fosun Pharma. Fosun Pharma memperoleh hak eksklusif untuk kandidat obat molekul kecil ACCRO AC-201 di Greater China. Siaran pers. 29 Agustus 2025.<br \/>2. Celltrion. FDA menyetujui indikasi yang diperluas untuk formulasi AVTOZMA (Tocilizumab-anoh) (IV) Avtozma dalam sindrom pelepasan sitokin (CRS). Siaran pers. 7 Agustus 2025.<br \/>3. Celltrion. US FDA menyetujui Avtozma Celltrion (Tocizumab-Anah), A Biocilar to Actemra. Siaran pers. 30 Januari,<br \/>4. Sanofi. Rilzabrutinib dari Sanofi mendapatkan penunjukan yatim di UE untuk penyakit terkait IgG4. Siaran pers. 14 Agustus 2025.<br \/>5. Barton, C. Melihat melampaui vaksin Covid-19 berbasis mRNA untuk terapi inovatif. <em>Pharmtech.com<\/em>24 Juni 2025.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai.China-Jan. 8th 2022: Logo Fosun Pharma Company di gedung kantor di malam hari. Perusahaan farmasi Cina yang sebagian besar dimiliki oleh Fosun International | Kredit Gambar: \u00a9 Robert &#8211; Stock.adobe.com Shanghai-based Fosun Pharma has reached an agreement with Accro Bioscience to exclusively develop, manufacture and commercialize Accro&#39;s highly selective tyrosine kinase 2 (TYK2)\/Janus kinase 1 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":268,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-267","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Fosun pharma untuk secara eksklusif mengembangkan bioscience anti-inflamasi di Cina - Nova Anggreni, S.Farm, APT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/\" \/>\n<meta property=\"og:locale\" content=\"id_ID\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun pharma untuk secara eksklusif mengembangkan bioscience anti-inflamasi di Cina - Nova Anggreni, S.Farm, APT\" \/>\n<meta property=\"og:description\" content=\"Shanghai.China-Jan. 8th 2022: Logo Fosun Pharma Company di gedung kantor di malam hari. Perusahaan farmasi Cina yang sebagian besar dimiliki oleh Fosun International | Kredit Gambar: \u00a9 Robert &#8211; Stock.adobe.com Shanghai-based Fosun Pharma has reached an agreement with Accro Bioscience to exclusively develop, manufacture and commercialize Accro&#039;s highly selective tyrosine kinase 2 (TYK2)\/Janus kinase 1 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/\" \/>\n<meta property=\"og:site_name\" content=\"Nova Anggreni, S.Farm, APT\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-30T09:45:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cdn.sanity.io\/images\/0vv8moc6\/pharmtech\/c5d7149fbf2289aa45ced0d8d78cfbeaef098d2d-6240x4160.jpg?fit=crop&amp;auto=format\" \/>\n<meta name=\"author\" content=\"pythonsonline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ditulis oleh\" \/>\n\t<meta name=\"twitter:data1\" content=\"pythonsonline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimasi waktu membaca\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 menit\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/\"},\"author\":{\"name\":\"pythonsonline\",\"@id\":\"https:\/\/pythonsonline.com\/#\/schema\/person\/c1dd578cabc4e398492d9e25f7aff156\"},\"headline\":\"Fosun pharma untuk secara eksklusif mengembangkan bioscience anti-inflamasi di Cina\",\"datePublished\":\"2025-08-30T09:45:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/\"},\"wordCount\":645,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/pythonsonline.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/08\/c5d7149fbf2289aa45ced0d8d78cfbeaef098d2d-6240x4160-scaled.jpg\",\"articleSection\":[\"Blog\"],\"inLanguage\":\"id\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/\",\"url\":\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/\",\"name\":\"Fosun pharma untuk secara eksklusif mengembangkan bioscience anti-inflamasi di Cina - Nova Anggreni, S.Farm, APT\",\"isPartOf\":{\"@id\":\"https:\/\/pythonsonline.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/08\/c5d7149fbf2289aa45ced0d8d78cfbeaef098d2d-6240x4160-scaled.jpg\",\"datePublished\":\"2025-08-30T09:45:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#breadcrumb\"},\"inLanguage\":\"id\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"id\",\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#primaryimage\",\"url\":\"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/08\/c5d7149fbf2289aa45ced0d8d78cfbeaef098d2d-6240x4160-scaled.jpg\",\"contentUrl\":\"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/08\/c5d7149fbf2289aa45ced0d8d78cfbeaef098d2d-6240x4160-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Beranda\",\"item\":\"https:\/\/pythonsonline.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun pharma untuk secara eksklusif mengembangkan bioscience anti-inflamasi di Cina\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pythonsonline.com\/#website\",\"url\":\"https:\/\/pythonsonline.com\/\",\"name\":\"Nova Anggreni, S.Farm, APT\",\"description\":\"Keahlian Farmasi Bertemu Kekuatan Python\",\"publisher\":{\"@id\":\"https:\/\/pythonsonline.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pythonsonline.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"id\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/pythonsonline.com\/#organization\",\"name\":\"Nova Anggreni, S.Farm, APT\",\"url\":\"https:\/\/pythonsonline.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"id\",\"@id\":\"https:\/\/pythonsonline.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/04\/novapylogo.png\",\"contentUrl\":\"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/04\/novapylogo.png\",\"width\":1080,\"height\":416,\"caption\":\"Nova Anggreni, S.Farm, APT\"},\"image\":{\"@id\":\"https:\/\/pythonsonline.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/pythonsonline.com\/#\/schema\/person\/c1dd578cabc4e398492d9e25f7aff156\",\"name\":\"pythonsonline\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"id\",\"@id\":\"https:\/\/pythonsonline.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ce18169fbfa6b96654e8a84f663d2fe6cd783a46c25e8318605272fd245c2e8c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ce18169fbfa6b96654e8a84f663d2fe6cd783a46c25e8318605272fd245c2e8c?s=96&d=mm&r=g\",\"caption\":\"pythonsonline\"},\"sameAs\":[\"https:\/\/pythonsonline.com\"],\"url\":\"https:\/\/pythonsonline.com\/index.php\/author\/pythonsonline\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fosun pharma untuk secara eksklusif mengembangkan bioscience anti-inflamasi di Cina - Nova Anggreni, S.Farm, APT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/","og_locale":"id_ID","og_type":"article","og_title":"Fosun pharma untuk secara eksklusif mengembangkan bioscience anti-inflamasi di Cina - Nova Anggreni, S.Farm, APT","og_description":"Shanghai.China-Jan. 8th 2022: Logo Fosun Pharma Company di gedung kantor di malam hari. Perusahaan farmasi Cina yang sebagian besar dimiliki oleh Fosun International | Kredit Gambar: \u00a9 Robert &#8211; Stock.adobe.com Shanghai-based Fosun Pharma has reached an agreement with Accro Bioscience to exclusively develop, manufacture and commercialize Accro&#39;s highly selective tyrosine kinase 2 (TYK2)\/Janus kinase 1 [&hellip;]","og_url":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/","og_site_name":"Nova Anggreni, S.Farm, APT","article_published_time":"2025-08-30T09:45:47+00:00","og_image":[{"url":"https:\/\/cdn.sanity.io\/images\/0vv8moc6\/pharmtech\/c5d7149fbf2289aa45ced0d8d78cfbeaef098d2d-6240x4160.jpg?fit=crop&amp;auto=format","type":"","width":"","height":""}],"author":"pythonsonline","twitter_card":"summary_large_image","twitter_misc":{"Ditulis oleh":"pythonsonline","Estimasi waktu membaca":"3 menit"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#article","isPartOf":{"@id":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/"},"author":{"name":"pythonsonline","@id":"https:\/\/pythonsonline.com\/#\/schema\/person\/c1dd578cabc4e398492d9e25f7aff156"},"headline":"Fosun pharma untuk secara eksklusif mengembangkan bioscience anti-inflamasi di Cina","datePublished":"2025-08-30T09:45:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/"},"wordCount":645,"commentCount":0,"publisher":{"@id":"https:\/\/pythonsonline.com\/#organization"},"image":{"@id":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#primaryimage"},"thumbnailUrl":"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/08\/c5d7149fbf2289aa45ced0d8d78cfbeaef098d2d-6240x4160-scaled.jpg","articleSection":["Blog"],"inLanguage":"id","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/","url":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/","name":"Fosun pharma untuk secara eksklusif mengembangkan bioscience anti-inflamasi di Cina - Nova Anggreni, S.Farm, APT","isPartOf":{"@id":"https:\/\/pythonsonline.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#primaryimage"},"image":{"@id":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#primaryimage"},"thumbnailUrl":"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/08\/c5d7149fbf2289aa45ced0d8d78cfbeaef098d2d-6240x4160-scaled.jpg","datePublished":"2025-08-30T09:45:47+00:00","breadcrumb":{"@id":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#breadcrumb"},"inLanguage":"id","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/"]}]},{"@type":"ImageObject","inLanguage":"id","@id":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#primaryimage","url":"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/08\/c5d7149fbf2289aa45ced0d8d78cfbeaef098d2d-6240x4160-scaled.jpg","contentUrl":"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/08\/c5d7149fbf2289aa45ced0d8d78cfbeaef098d2d-6240x4160-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/pythonsonline.com\/index.php\/2025\/08\/30\/fosun-pharma-untuk-secara-eksklusif-mengembangkan-bioscience-anti-inflamasi-di-cina\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Beranda","item":"https:\/\/pythonsonline.com\/"},{"@type":"ListItem","position":2,"name":"Fosun pharma untuk secara eksklusif mengembangkan bioscience anti-inflamasi di Cina"}]},{"@type":"WebSite","@id":"https:\/\/pythonsonline.com\/#website","url":"https:\/\/pythonsonline.com\/","name":"Nova Anggreni, S.Farm, APT","description":"Keahlian Farmasi Bertemu Kekuatan Python","publisher":{"@id":"https:\/\/pythonsonline.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pythonsonline.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"id"},{"@type":"Organization","@id":"https:\/\/pythonsonline.com\/#organization","name":"Nova Anggreni, S.Farm, APT","url":"https:\/\/pythonsonline.com\/","logo":{"@type":"ImageObject","inLanguage":"id","@id":"https:\/\/pythonsonline.com\/#\/schema\/logo\/image\/","url":"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/04\/novapylogo.png","contentUrl":"https:\/\/pythonsonline.com\/wp-content\/uploads\/2025\/04\/novapylogo.png","width":1080,"height":416,"caption":"Nova Anggreni, S.Farm, APT"},"image":{"@id":"https:\/\/pythonsonline.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pythonsonline.com\/#\/schema\/person\/c1dd578cabc4e398492d9e25f7aff156","name":"pythonsonline","image":{"@type":"ImageObject","inLanguage":"id","@id":"https:\/\/pythonsonline.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ce18169fbfa6b96654e8a84f663d2fe6cd783a46c25e8318605272fd245c2e8c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ce18169fbfa6b96654e8a84f663d2fe6cd783a46c25e8318605272fd245c2e8c?s=96&d=mm&r=g","caption":"pythonsonline"},"sameAs":["https:\/\/pythonsonline.com"],"url":"https:\/\/pythonsonline.com\/index.php\/author\/pythonsonline\/"}]}},"_links":{"self":[{"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/posts\/267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/comments?post=267"}],"version-history":[{"count":0,"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/posts\/267\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/media\/268"}],"wp:attachment":[{"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/media?parent=267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/categories?post=267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pythonsonline.com\/index.php\/wp-json\/wp\/v2\/tags?post=267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}